A House Energy and Commerce Committee report suggests that Congress clarify the intent of the 340B drug discount program, promote transparency and grant the Health Resources and Services Administration sufficient regulatory administration and oversight authority, among other recommendations.
House committee recommends stronger oversight of 340B drug program
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.